ES2542842T3 - Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer - Google Patents

Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer Download PDF

Info

Publication number
ES2542842T3
ES2542842T3 ES02252414.4T ES02252414T ES2542842T3 ES 2542842 T3 ES2542842 T3 ES 2542842T3 ES 02252414 T ES02252414 T ES 02252414T ES 2542842 T3 ES2542842 T3 ES 2542842T3
Authority
ES
Spain
Prior art keywords
transfer agent
taurultam
taurolidine
administered
methylol transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02252414.4T
Other languages
English (en)
Spanish (es)
Inventor
H. Paul Redmond
Ruediger Stendel
Hanns Moehler
Rolf W. Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Application granted granted Critical
Publication of ES2542842T3 publication Critical patent/ES2542842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ES02252414.4T 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer Expired - Lifetime ES2542842T3 (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US28074801P 2001-04-03 2001-04-03
US280748P 2001-04-03
US28171201P 2001-04-06 2001-04-06
US28171301P 2001-04-06 2001-04-06
US28171101P 2001-04-06 2001-04-06
US28171001P 2001-04-06 2001-04-06
US281713P 2001-04-06
US281712P 2001-04-06
US281710P 2001-04-06
US281711P 2001-04-06
US28493401P 2001-04-20 2001-04-20
US28493301P 2001-04-20 2001-04-20
US284933P 2001-04-20
US284934P 2001-04-20

Publications (1)

Publication Number Publication Date
ES2542842T3 true ES2542842T3 (es) 2015-08-12

Family

ID=27569569

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02252414.4T Expired - Lifetime ES2542842T3 (es) 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer
ES10009649.4T Expired - Lifetime ES2562827T3 (es) 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10009649.4T Expired - Lifetime ES2562827T3 (es) 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer

Country Status (5)

Country Link
US (1) US20030027818A1 (enExample)
EP (2) EP2258373B1 (enExample)
JP (2) JP2002363102A (enExample)
CA (2) CA2379734C (enExample)
ES (2) ES2542842T3 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20020177571A1 (en) * 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ATE513471T1 (de) * 2003-04-21 2011-07-15 Epeius Biotechnologies Corp Verfahren und zusammensetzungen zur behandlung von erkrankungen
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
NZ567550A (en) * 2005-11-29 2011-08-26 Novartis Ag Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
CA2636217C (en) * 2006-01-06 2014-02-25 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
CN101528195B (zh) * 2006-09-07 2012-03-28 埃德盖斯特利希索恩化学工业股份公司 羟甲基转移剂在制备治疗骨癌的药物中的用途
BR112012030641B8 (pt) * 2010-06-01 2022-06-14 Geistlich Pharma Ag Usos e composições para terapia farmacêutica oral
KR20180105112A (ko) * 2015-08-31 2018-09-27 코르메딕스, 인코포레이티드 나노섬유 웹을 이용한 활성제의 전달
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
EP3843746A4 (en) * 2018-08-28 2022-10-19 CorMedix Inc. NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS
JP2021535167A (ja) * 2018-08-31 2021-12-16 コーメディクス・インコーポレーテッド 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療
WO2020234829A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
GB9600426D0 (en) * 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
US5858990A (en) 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
BR9809149A (pt) 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US6303596B1 (en) * 1997-05-22 2001-10-16 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
CA2379734C (en) 2010-06-29
EP2258373A1 (en) 2010-12-08
US20030027818A1 (en) 2003-02-06
JP2002363102A (ja) 2002-12-18
EP1247524B1 (en) 2015-06-24
ES2562827T3 (es) 2016-03-08
JP2009138003A (ja) 2009-06-25
EP2258373B1 (en) 2016-01-27
CA2692295A1 (en) 2002-10-03
CA2379734A1 (en) 2002-10-03
EP1247524A1 (en) 2002-10-09
JP5232678B2 (ja) 2013-07-10
CA2692295C (en) 2013-06-25

Similar Documents

Publication Publication Date Title
ES2542842T3 (es) Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer
ES2150889T1 (es) Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii.
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
PA8542701A1 (es) Composición parenteral reconstituible
Fossgreen A survey of current publications
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
ES2060199T3 (es) Forma galenica para administrar oralmente glipicida hipoglicemica.
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
CO6220962A2 (es) Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
MX9700081A (es) Composiciones farmaceuticas de tacrina.
UY26926A1 (es) Derivados de la quinolina y quinazolina
MX9203444A (es) Medicamentos.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
DK349889D0 (da) Anvendelse af polyacrylater til fremstilling af et laegemiddel
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
AR046951A1 (es) Moduladores de los receptores nucleares de hormonas esteroides triciclicos
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
RU2003105901A (ru) Противовоспалительное лекарственное средство
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina